CClinicalTrials.gg
CompletedNCT03285750GPR120Updated Jun 15, 2023

Expression of G-protein Coupled Receptor 120 Receptor in Adipose Tissue of German Diabetes Center Cohort Subjects

An observational study in Type 2 Diabetes, sponsored by German Diabetes Center. Completed at 1 site in Germany. Open to participants aged 20 Years to 69 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-06-15.

Sponsored by German Diabetes Center · Observational

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
50
Ages
20 Years to 69 Years
Sex
All
01

Study summary

G-protein coupled receptor 120 (GPR120) is a G-protein-coupled receptor whose endogenous ligands have been identified as long-chain fatty acids. Recently, it has been shown that GPR120 expression in human adipose tissue is higher in obese than in lean individuals. Interestingly, a GPR120 deficient mouse model presents an unfavorable phenotype when fed a high-fat diet with obesity, glucose intolerance and fatty liver, characteristics also found in type 2 diabetes (T2D).

Moreover, in obese subjects, a single nucleotide polymorphism (R270H) has been identified that inhibits GPR120 signaling activity.

The investigators now want to investigate if GPR120 expression in adipose tissue may be altered in patients with T2D compared to non-diabetic subjects and might contribute to diabetes-associated metabolic changes. Additionally, the investigators want to assess the frequency of the R270H mutant in T2D.

02

Conditions studied

  • Type 2 Diabetes

Keywords

  • GPR120
  • Adipose tissue
  • Type 2 diabetes
03

Who can participate

Ages eligible
20 Years to 69 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients with recently diagnosed type 2 diabetes (up to one year from diagnosis) and age- and weight-matched normoglycemic controls

Inclusion criteria

  • Type 2 diabetes mellitus / normoglycemia
  • BMI \< 27,5 or > 30 kg/m2
  • Age 20 - 69 years

Exclusion criteria

Exclusion Criteria:

  • severe chronic diseases
  • anemia
  • medication altering fatty acid metabolism
04

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
50 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Diabetic group

    Patients with recently diagnosed type 2 diabetes

  • Controls

    Age- and BMI-matched normoglycemic subjects

05

What researchers measure

Primary outcomes

  1. GPR120 expression in adipose tissue

    GPR expression is measured in adipose tissue of recently diagnosed type 2 diabetic patients and age- and BMI-matched normoglycemic controls

    Time frame: Expression measured at baseline (day 1)

06

Study locations

1 site
  • German Diabetes Center
    Duesseldorf, Nordrhein-Westfalen 40225, Germany
07

Registry details

Key details

Study ID
NCT03285750
Lead sponsor
German Diabetes Center
Responsible party
Sponsor
First posted
Sep 18, 2017
Start date
Aug 2013
Primary completion
Sep 2017
Completion
Sep 2017
Last update
Jun 15, 2023

Study contacts

Michael Roden, Prof., MD
principal investigator · German Diabetes Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion